An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 1, 2012, Pages 37-45

  Khabele, Dineo ^a,b   Fadare, Oluwole ^a,b   Liu, Annie Y ^a   Wilson, Andrew J ^a   Wass, Erika ^a   Osteen, Kevin ^a,b   Crispens, Marta A ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Fallopian tube carcinoma; Orthotopic model; Pelvic serous carcinoma; STIC

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ANIMAL; ARTICLE; CANCER STAGING; CASE REPORT; CYSTADENOCARCINOMA; DRUG SCREENING; FEMALE; HUMAN; METHODOLOGY; MOUSE; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; PRECANCER; UTERINE TUBE TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM STAGING; PRECANCEROUS CONDITIONS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856753398     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Stewart SL, Wike JM, Foster SL and Michaud F. The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol 2007; 107: 392-397.
2. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG and Crum CP. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-169.
3. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
4. Wethington SL, Herzog TJ, Seshan VE, Bansal N, Schiff PB, Burke WM, Cohen CJ and Wright JD. Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. Cancer 2008; 113: 3298-3306.
5. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U. Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1: S145-160.
6. Bast RC Jr, Hennessy B and Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009; 9: 415-428.
7. Landen CN Jr, Birrer MJ and Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26: 995-1005.
8. TCGA. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
9. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol 2009; 112: 275-281.
10. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH and de Bono JS. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
11. Mehra K, Mehrad M, Ning G, Drapkin R, McKeon FD, Xian W and Crum CP. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed) 2011; 3: 625-634.
12. Seidman JD, Zhao P and Yemelyanova A. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 2011; 120: 470-473.
13. Przybycin CG, Kurman RJ, Ronnett BM, Shih Ie M and Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010; 34: 1407-1416.
14. Carlson JW, Jarboe EA, Kindelberger D, Nucci MR, Hirsch MS and Crum CP. Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications. Int J Gynecol Pathol 2010; 29: 310-314.
15. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS and Muto MG. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25: 3985-3990.
16. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011; 42: 918-931.
17. Elkas JC, Baldwin RL, Pegram M, Tseng Y, Slamon D and Karlan BY. A human ovarian carcinoma murine xenograft model useful for preclinical trials. Gynecol Oncol 2002; 87: 200-206.
18. Weissman A, Gotlieb L, Colgan T, Jurisicova A, Greenblatt EM and Casper RF. Preliminary experience with subcutaneous human ovarian cortex transplantation in the NOD-SCID mouse. Biol Reprod 1999; 60: 1462-1467.
19. Xu Y, Silver DF, Yang NP, Oflazoglu E, Hempling RE, Piver MS and Repasky EA. Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol 1999; 72: 161-170.
20. Silver DF, Hempling RE, Piver MS and Repasky EA. Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient mice. Gynecol Oncol 2000; 77: 377-382.
21. Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC Jr, Kudelka AP, Kavanagh JJ and Giovanella BC. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res 2003; 9: 845-852.
22. Cho KR, Shih IM. Ovarian Cancer. Annu Rev Pathol 2009; 4: 287-313.
23. Levanon K, Ng V, Piao HY, Zhang Y, Chang MC, Roh MH, Kindelberger DW, Hirsch MS, Crum CP, Marto JA and Drapkin R. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 2010; 29: 1103-1113.
24. Jazaeri AA, Bryant JL, Park H, Li H, Dahiya N, Stoler MH, Ferriss JS and Dutta A. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia 2011; 13: 899-911.
25. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J and Sidransky D. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011; 10: 1311-1316.
26. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM and Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598.
27. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A and Hidalgo M. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006; 12: 4652-4661.